Hirsutism in the Absence of Hyperandrogenism

Hirsutism is traditionally viewed as a clinical sign of androgen hormone excess in the body. Excessive terminal hair growth in androgen-dependent areas of the female body – particularly the face, chest, abdomen, and back – is commonly linked to conditions such as polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia, ovarian hyperthecosis, or androgen-secreting tumors. However, a substantial subset of women can present with clinically significant hirsutism despite apparently normal circulating androgen concentrations – as seen with apparently normal blood test results. This phenomenon has historically been termed “idiopathic hirsutism,” (the language equivalent of dermatologists shrugging their shoulders). However, that terminology has been the subject of much debate in recent years.

The concept that hirsutism can occur without overt biochemical hyperandrogenism has become increasingly important as understanding of peripheral androgen metabolism, androgen receptor biology, and local follicular steroidogenesis has evolved. Modern evidence suggests that many women previously classified as having “idiopathic” disease may actually possess subtle or localized forms of androgen excess activity that are not adequately detected by routine endocrine blood test testing.

Defining Normoandrogenic Hirsutism: Idiopathic or normoandrogenic hirsutism is generally defined as excessive terminal hair growth in women who demonstrate:

• Normal ovulatory menstrual cycles
• Normal ovarian morphology
• Normal serum androgen levels
• No identifiable endocrine disorder

Depending on the population studied and diagnostic criteria used, idiopathic hirsutism may account for approximately 5–20% of hirsutism cases seen in dermatology clinics.

Yet this definition creates an apparent biological paradox. Hair follicles in androgen-sensitive body regions generally require androgenic hormone stimulation to transform fine vellus hairs into coarse pigmented terminal hairs. If androgens circulating in the blood are “normal,” why does androgen-dependent hair growth occur?

This paradox has driven a major shift in thinking over the past decade. Many investigators and dermatologists now believe that hirsutism without hyperandrogenemia reflects abnormalities in local androgen action in the skin and hair follicles rather than a complete absence of androgen dysregulation in the body.

The Hair Follicle as an Independent Endocrine Organ: The hair follicle is no longer regarded as a passive target of circulating hormones. Instead, it functions as a highly active peripheral endocrine structure capable of synthesizing, converting, and metabolizing steroid hormones locally.

Within the pilosebaceous unit (the hair follicle plus the attached sebaceous gland), enzymes such as:

• 5α-reductase
• Steroid sulfatase
• 17β-hydroxysteroid dehydrogenase
• Aromatase

can substantially alter local androgen availability independent of serum hormone concentrations.

One of the most important mechanisms involves increased 5α-reductase activity within the skin. This enzyme converts testosterone into dihydrotestosterone (DHT), which has substantially greater affinity for the androgen receptor in responsive cells. Even normal circulating testosterone concentrations may therefore produce exaggerated follicular androgenic signaling if local DHT generation is enhanced.

Several studies have demonstrated increased expression of steroidogenic enzymes in the skin of women who were initially diagnosed with idiopathic hirsutism. These findings support the concept that peripheral androgen amplification may underlie many cases previously considered endocrinologically “normal.”

Androgen Receptor Sensitivity: Another important mechanism involves altered androgen receptor sensitivity.

Hair follicles vary markedly in their responsiveness to androgens depending on anatomical location, ethnicity, genetics, and polymorphisms in the genes that code for androgen receptors. Some women may therefore develop clinically significant hirsutism despite blood test androgen concentrations that apparently fall within laboratory reference ranges.

Particular attention has focused on CAG repeat polymorphisms within the androgen receptor gene. Shorter CAG repeat lengths are associated with increased receptor transcriptional activity. Women harboring more sensitive receptor variants may exhibit amplified androgen responses despite apparently normal endocrine profiles.

This concept parallels other endocrine conditions in which tissue responsiveness differs despite normal circulating hormone levels. Thus, serum androgen concentrations alone may inadequately reflect total androgenic activity at the tissue level.

Relative Rather Than Absolute Hyperandrogenism: An emerging concept is that many women with “normal” androgen levels may still exhibit relative hyperandrogenemia.

Laboratory reference ranges for testosterone and other androgens are often broad, method-dependent, and poorly standardized between institutions. A woman whose androgen levels lie near the upper end of the normal female range may still experience excessive androgenic effects, especially when combined with increased peripheral sensitivity.

Furthermore, conventional immunoassays frequently lack sensitivity at the low concentrations typical of female androgen physiology. Liquid chromatography–mass spectrometry (LC-MS/MS) methods have revealed subtle androgen elevations that older assays can miss.

Consequently, some women categorized as normoandrogenic may actually possess mild biochemical hyperandrogenism undetectable using routine testing methodologies. While LC-MS/MS is a more sensitive method of analysing blood hormone concentrations, it is expensive and so not routinely available for screening patients.

The Role of 11-Oxygenated Androgens: One of the most important recent developments in androgen biology has been the recognition of 11-oxygenated androgens.

These adrenal-derived steroids, including:

• 11-ketotestosterone
• 11β-hydroxyandrostenedione
• 11-ketoandrostenedione

possess particularly potent androgenic activity and may contribute substantially to female hyperandrogenic states.

Importantly, these steroids are not routinely measured in standard endocrine panels. Recent studies suggest they may contribute to androgenic manifestations even when conventional testosterone and DHEAS concentrations appear normal.

This research area remains under active investigation and may eventually redefine how “normal androgen levels” are interpreted clinically.

Is Normoandrogenic Hirsutism an Early Form of PCOS: Another major controversy concerns whether idiopathic hirsutism truly represents a distinct entity or instead reflects an early or incomplete form of PCOS.

Some women with initially normal androgen profiles later develop overt biochemical hyperandrogenism, menstrual irregularity, or polycystic ovarian morphology over time. Others demonstrate subtle insulin resistance or metabolic dysfunction despite regular menstrual cycles.

This has led some investigators to argue that idiopathic hirsutism is not genuinely “idiopathic” but instead represents a mild spectrum disorder within the broader hyperandrogenic-PCOS continuum.

However, not all women with normoandrogenic hirsutism progress to PCOS, and substantial heterogeneity likely exists within this population.

Ethnicity and Hair Follicle Biology: Ethnicity significantly influences the clinical presentation of hirsutism.

Mediterranean, Middle Eastern, and South Asian women often exhibit greater terminal hair density than East Asian women despite similar androgen levels. Genetic variation in follicular sensitivity, enzyme activity, and androgen receptor function likely contributes to these differences.

This creates challenges when applying universal Ferriman–Gallwey scoring thresholds across diverse populations. A score considered abnormal in one ethnic group may fall within the normal range in another.

Consequently, modern guidelines increasingly emphasize individualized clinical interpretation rather than rigid numeric cutoffs alone.

Diagnostic Evaluation: Although hirsutism without hyperandrogenism is often benign, careful evaluation continues to be essential to exclude serious endocrine disease.

Initial assessment typically includes:

• Detailed menstrual history
• Rate of progression
• Family history
• Medication review
• Ferriman–Gallwey scoring
• Assessment for virilization

Rapidly progressive hirsutism, deepening voice, or severe androgenic alopecia raise concern for androgen-secreting tumors.

Laboratory testing commonly includes:

• Total and free testosterone
• DHEAS
• SHBG
• 17-hydroxyprogesterone
• Prolactin
• TSH

Additional testing may be warranted depending on clinical suspicion. Importantly, normal laboratory findings do not exclude clinically meaningful androgen dysregulation at the local tissue level.

Cosmetic and Physical Therapies: Management depends on symptom severity, reproductive goals, and patient preference. Many women primarily seek reduction in visible hair growth. Common approaches include:

• Shaving
• Waxing
• Depilatory creams
• Electrolysis
• Laser hair reduction

Laser therapy has become particularly important for long-term management. Multiple studies demonstrate significant improvements in quality of life following laser treatment.

However, maintenance sessions are often required because hormonal or follicular drivers persist.

Pharmacologic Therapy: Even in normoandrogenic women, antiandrogen therapy may provide benefit because the disorder often reflects increased peripheral androgen action rather than absent androgen involvement.

Common therapies include:

• Combined oral contraceptives
• Spironolactone
• Finasteride
• Cyproterone acetate (not available in all countries)
• Topical eflornithine

These agents reduce androgen production, block androgen receptors, or impair follicular androgen metabolism.

Response is generally slow because terminal hair follicles require months to cycle and change in size. Most patients require at least 6–12 months of treatment before substantial improvement becomes evident.

Psychological Impact: The psychological burden of hirsutism is frequently underestimated.

Women with hirsutism often experience anxiety, embarrassment, depression, impaired self-esteem, and social withdrawal regardless of endocrine severity. Interestingly, psychological distress correlates poorly with objective Ferriman–Gallwey scores. Even mild hirsutism may cause major emotional distress depending on cultural and personal factors.

Modern management increasingly recognizes the importance of psychosocial support alongside endocrine treatment.

Conclusion: Hirsutism in the absence of overt hyperandrogenism is no longer viewed as a completely mysterious or truly “idiopathic” condition. Advances in hair follicle biology, peripheral steroid metabolism, androgen receptor signaling, and analytical endocrinology have revealed that many women possess subtle forms of localized androgen excess despite normal serum hormone concentrations.

The hair follicle itself acts as an active endocrine microenvironment capable of amplifying androgenic signaling independently of systemic hormone levels. Increased local DHT production, altered receptor sensitivity, relative hyperandrogenemia, and newly recognized 11-oxygenated androgens likely all contribute to the condition.

As understanding evolves, the distinction between idiopathic hirsutism and mild hyperandrogenic disorders such as PCOS may become increasingly blurred. Future advances in steroid profiling and molecular diagnostics will likely redefine current classifications and improve individualized treatment strategies.

Bibliography